CoChat

Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes

Open access
Barata, Llilda, Feitosa, Mary F., Bielak, Lawrence F., Halligan, Brian, Baldridge, Abigail S., Guo, Xiuqing, Yerges‐Armstrong, Laura M., Smith, Albert V., Yao, Jie, Palmer, Nicholette D., VanWagner, Lisa B., Carr, J. Jeffrey, Chen, Yii‐Der I., Allison, Matthew, Budoff, Matthew J., Handelman, Samuel K., Kardia, Sharon L.R., Mosley, Thomas H., Ryan, Kathleen, Harris, Tamara B., Launer, Lenore J., Gudnason, Vilmundur, Rotter, Jerome I., Fornage, Myriam, Rasmussen‐Torvik, Laura J., Borecki, Ingrid B., O’Connell, Jeffrey R., Peyser, Patricia A., Speliotes, Elizabeth K., Province, Michael A. · 2019 · Hepatology Communications
Cited by 59

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

The accumulation of excess fat in the liver (hepatic steatosis) in the absence of heavy alcohol consumption causes nonalcoholic fatty liver disease (NAFLD), which has become a global epidemic. Identifying metabolic risk factors that interact with the genetic risk of NAFLD is important for reducing disease burden. We tested whether serum glucose, insulin, insulin resistance, triglyceride (TG), low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, body mass index (BMI), and waist‐to‐hip ratio adjusted for BMI interact with genetic variants in or near the patatin‐like phospholipase domain containing 3 (PNPLA3) gene, the glucokinase regulatory protein (GCKR) gene, the neurocan/transmembrane 6 superfamily member 2 (NCAN/TM6SF2) gene, and the lysophospholipase‐like 1 (LYPLAL1) gene to exacerbate hepatic steatosis, estimated by liver attenuation. We performed association analyses in 10 population‐based cohorts separately and then meta‐analyzed results in up to 14,751 individuals (11,870 of European ancestry and 2,881 of African ancestry). We found that PNPLA3‐rs738409 significantly interacted with insulin, insulin resistance, BMI, glucose, and TG to increase hepatic steatosis in nondiabetic individuals carrying the G allele. Additionally, GCKR‐rs780094 significantly interacted with insulin, insulin resistance, and TG. Conditional analyses using the two largest European ancestry cohorts in the study showed that insulin levels accounted for most of the interaction of PNPLA3‐rs738409 with BMI, glucose, and TG in nondiabetic individuals. Insulin, PNPLA3‐rs738409, and their interaction accounted for at least 8% of the variance in hepatic steatosis in these two cohorts. Conclusion: Insulin resistance, either directly or through the resultant elevated insulin levels, more than other metabolic traits, appears to amplify the PNPLA3‐rs738409‐G genetic risk for hepatic steatosis. Improving insulin resistance in nondiabetic individuals carrying PNPLA3‐rs738409‐G may preferentially decrease hepatic steatosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep4.1353

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

Metadata

Authors
Barata, L., Feitosa, M. F., Bielak, L. F., Halligan, B., Baldridge, A. S., Guo, X., Yerges‐Armstrong, L. M., Smith, A. V., Yao, J., Palmer, N. D., VanWagner, L. B., Carr, J. J., Chen, Y. I., Allison, M., Budoff, M. J., Handelman, S. K., Kardia, S. L. R., Mosley, T. H., Ryan, K., Harris, T. B., Launer, L. J., Gudnason, V., Rotter, J. I., Fornage, M., Rasmussen‐Torvik, L. J., Borecki, I. B., O’Connell, J. R., Peyser, P. A., Speliotes, E. K., & Province, M. A.
Venue
Hepatology Communications
Published
2019-04-18
Volume
3
Issue
7
Pages
894-907
ISSN
2471-254X (ISSN-L)
OpenAlex
W2939644650
Cited by
59
References
10
FWCI
4.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.